BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Alzheimer's Drug Discovery Foundation Funds ALS Biopharma LLC to Develop Small Molecules for Alzheimer's Disease


1/27/2011 8:10:00 AM

NEW YORK, Jan. 27, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $195,000 to ALS Biopharma, LLC to develop therapeutics targeted at clearing toxic proteins implicated in Alzheimer's disease.

(Logo: http://photos.prnewswire.com/prnh/20090805/DC57332LOGO)

The program will identify and develop small-molecule brain-penetrant inducers of heat shock protein 70 (Hsp70). Hsp70 clears two proteins believed to be involved in Alzheimer's disease, the toxic form of tau protein and beta-amyloid. The company first developed the Hsp70 program to clear insoluble protein deposits seen in amyotrophic lateral sclerosis (ALS).

"We greatly appreciate the ADDF funding because it allows us to explore small-molecule regulation of the heat shock response to treat neurological disorders by taking advantage of our established competencies in pharmacology and medicinal chemistry," said Dr. Allen Reitz, CEO of ALS Biopharma.

"We are excited to support ALS Biopharma's innovative program in this target area," said Howard Fillit, MD, Executive Director of the ADDF. "Small molecule therapeutics targeting Hsp70 would result in a disease-modifying therapy for Alzheimer's disease and could also be employed in related neurodegenerative diseases, such as ALS, Parkinson's and Huntington's."

About the Alzheimer's Drug Discovery Foundation (www.AlzDiscovery.org)

The ADDF (www.AlzDiscovery.org) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery and development programs in academic centers and biotechnology companies in 17 countries.

About ALS Biopharma, LLC (www.alsbiopharma.com)

ALS Biopharma, LLC (ALSBio) is an emerging biotechnology company located at the Pennsylvania Biotechnology Center in Doylestown, Pennsylvania. ALSBio is an emerging biotechnology company dedicated to the discovery of therapeutics and diagnostics for the treatment of the debilitating neurological orphan indication of amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease) and related disorders such as Alzheimer's disease. Modern methods in drug discovery are used including compound library synthesis and screening. In partnership with top academic and industrial laboratories, ALSBio is researching both small molecule and biologic protein-based approaches to provide therapeutic relief to patients in need.

SOURCE Alzheimer's Drug Discovery Foundation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES